EI
CBIO

EAM Investors’s Crescent Biopharma CBIO Stock Holding History

EAM Investors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,872
Closed -$4.82M – 317
2017
Q4 		$4.82M Sell
2,872
-838
-23% -$1.11M 0.86% 4
2017
Q3 		$5.19M Buy
3,710
+323
+10% +$379K 0.69% 24
2017
Q2 		$3.78M Buy
+3,387
New +$2.8M 0.62% 33

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's CBIO Position: Q1 2018 in Review

EAM Investors sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 2,872 shares — an estimated $4.82M sold.

EAM Investors first reported a position in CBIO in Q2 2017 and held it in 3 quarters. The position peaked at $5.19M in Q3 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

  • EAM Investors reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
  • EAM Investors sold 2,872 Crescent Biopharma shares in Q1 2018, an estimated $4.82M.
  • EAM Investors first reported a position in Crescent Biopharma in Q2 2017 and held it in 3 quarters.
  • EAM Investors's Crescent Biopharma position peaked at $5.19M in Q3 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on EAM Investors's 13F filing for Q1 2018, filed 14 May 2018.